Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Shanghai BDgene Technology
Main focus: mRNA-mediated delivery of gene-editing systems
Company stage: Clinical
Diseases: wet age-related macular degeneration (wAMD), glucoma, multiple other undisclosed diseases
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Shanghai, China
Shanghai BDgene Technology uses it proprietary technology, BDmRNA, to deliver gene-editing systems for the treatment of genetic diseases. The technology is thought to reduce the probability of off-target gene editing, and improve the safety of gene-editing medicines. Currently, the company is developing multiple pre-clinical programmes.